ClinicalTrials.Veeva

Menu

Role of Inflammatory Markers in Sepsis

N

National Cancer Institute, Egypt

Status

Enrolling

Conditions

Diagnostic

Treatments

Diagnostic Test: Serology tests

Study type

Observational

Funder types

Other

Identifiers

NCT06111963
AP2305-301-001

Details and patient eligibility

About

A diagnostic and prognostic study, in which the expression of CD64 in activated neutrophils and CD64 and IL17A regulatory T cells in patients with sepsis will be evaluated as a probable marker for sepsis as a primary objective

Enrollment

60 estimated patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Cancer patients admitted to the surgical ICU following cancer related surgeries and diagnosed with sepsis

Exclusion criteria

  • Refusal of patient or patient guardian to participate.
  • Intraoperative massive blood loss and massive blood transfusion
  • Patients with impaired preoperative kidney or liver function tests

Trial design

60 participants in 2 patient groups

Septic patients
Treatment:
Diagnostic Test: Serology tests
Non Septic patients
Treatment:
Diagnostic Test: Serology tests

Trial contacts and locations

1

Loading...

Central trial contact

Walaa Y Elsabeeny, MD; Ahmed Samir, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems